Research Services
Our liquid biopsy solutions deliver precise circulating tumor DNA testing to support cancer research, therapy evaluation, and biomarker development.
Specialized ctDNA Analytics for Research and Development
Our liquid biopsy MRD solutions combine analytical precision with clinical expertise. The Vista platform enables highly sensitive MRD detection and circulating tumor DNA test applications, ensuring accurate therapy response monitoring and early relapse identification in research and clinical trials.
Vista Technology
Proprietary ctDNA analysis platform with exceptional sensitivity, detects very small amounts of tumor DNA
Clinical Expertise
Proven experience in clinical validation studies for lymphomas with significant prognostic results
Tailored Solutions
Customized assay development and study-specific adaptations for different tumor entities
Our Core Services
MRD Assays (Minimal Residual Disease)
Highly sensitive circulating tumor DNA detection for minimal residual disease (MRD) across multiple cancer types, enabling three-stage patient monitoring:
- Genotyping to identify patient-specific mutations
- MRD monitoring during and after therapy
- Early relapse detection in follow-up care
Ideal for lymphomas and solid tumors.
Learn more about our
liquid biopsy lymphomaresearch applications.
Custom Assay Development
Development of customized liquid biopsy diagnostics for specific research and clinical needs:
- Tumor-specific gene panel development
- Validation for new indications
- Adaptation to study-specific requirements
- Technical and analytical validation
Applicable for pharmaceutical, biotech, and academic research projects.
Clinical Study Support
Comprehensive support for all clinical study phases:
- Study design and biomarker strategy
- Regulatory consultation and documentation
- Sample logistics and management
- Data analysis and reporting
Applicable for Phase I–III studies and companion diagnostic programs.
Biomarker Discovery
Identification and validation of circulating tumor DNA biomarkers for translational and clinical research:
- Prognostic and predictive biomarker discovery
- Therapy response monitoring
- Resistance mechanism identification
- Combined biomarker panels development
Enabling breakthroughs in drug development and personalized medicine.
Research Focus Areas
Hematological Malignancies
Established Expertise: Clinically validated tests for B-cell lymphomas and Hodgkin lymphomas with proven prognostic significance.
Solid Tumors
In Development: CancerVista for solid tumors with tumor-specific gene panels. Currently available for research use only (RUO).
Collaboration Process
Needs Analysis
Define research goals, study design, and technical requirements.
Assay Development
Adapt or create Vista assays for your specific study.
Validation
Conduct technical and clinical validation per regulatory standards.
Implementation
Perform sample analysis, data evaluation, and provide ongoing project support.
Quality Standards & Regulation
LIQOMICS operates under strict quality assurance and international standards:
RiliBÄK-compliant
Quality assurance according to German regulations
ISO Standards
International laboratory quality compliance
GDPR-compliant
Secure and ethical data processing
Validated Reporting
All results undergo technical and medical validation
References
1 Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024
2 Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024
Start Your Research Project
Contact us for a non-binding consultation regarding your liquid biopsy diagnostics and circulating tumor DNA detection requirements.